Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.850EUR

Average target price

9.265EUR

Spread / Average Target

+400.81%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI

Market Cap	45.85M 53.11M 42.98M 39.24M 73.82M 5.07B 74.14M 510M 199M 2.56B 199M 195M 8.49B	P/E 2026 *	-2.98x	P/E 2027 *	-2.8x
Enterprise Value	38.55M 44.65M 36.14M 32.99M 62.07M 4.26B 62.34M 428M 167M 2.15B 168M 164M 7.14B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
08-06	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT

08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
08-06	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation : Pentixapharm Holding AG

Latest news : Pentixapharm Holding AG

Press Releases : Pentixapharm Holding AG

News in other languages : Pentixapharm Holding AG

Price Extremes

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	53.21M
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.47%	+112.05%	1,047B
JOHNSON & JOHNSON	+0.85%	-0.81%	+52.77%	+63.15%	646B
ABBVIE INC.	-1.03%	-3.58%	+22.87%	+73.29%	451B
ROCHE HOLDING AG	-1.46%	-4.50%	+37.43%	+38.41%	355B
NOVARTIS AG	-0.72%	-2.89%	+21.86%	+36.79%	291B
ASTRAZENECA PLC	-1.19%	-2.21%	+1.35%	+12.29%	252B
AMGEN INC.	-1.05%	-1.57%	+51.40%	+68.55%	234B
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.29%	203B
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+29.42%	+89.10%	181B
Average	-0.68%	-2.68%	+28.88%	+48.82%	406.59B
Weighted average by Cap.	-0.46%	-3.46%	+38.66%	+65.51%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -25.83M -20.9M -19.09M -35.91M -2.46B -36.06M -248M -96.76M -1.25B -96.95M -94.85M -4.13B	-23.5M -27.22M -22.03M -20.11M -37.84M -2.6B -38M -261M -102M -1.31B -102M -99.95M -4.35B
Net Debt	-7.3M -8.46M -6.84M -6.25M -11.75M -806M -11.8M -81.13M -31.67M -408M -31.74M -31.05M -1.35B	12.3M 14.25M 11.53M 10.53M 19.8M 1.36B 19.89M 137M 53.37M 687M 53.48M 52.32M 2.28B